Sanofi US
Cambridge
Massachusetts
United States
208 articles about Sanofi US
-
Companies have already begun their announcements of new clinical studies for various treatment settings in preparation for ASCO 2021.
-
The high court’s decision will prevent Sandoz from launching its biosimilar to Amgen’s blockbuster rheumatoid arthritis drug.
-
Sanofi and GSK expect to launch a global pivotal Phase III trial of its COVID-19 vaccine in the coming week.
-
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
-
Cold Agglutinin Disease Associated with Greater Than Twofold Increased Risk of Mortality in First Five Years After Diagnosis
6/18/2018
New study is first to identify an increased risk of death in people with cold agglutinin disease compared to the general population
-
Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel
6/18/2018
Mr. Coppola previously held related positions at Sanofi.
-
Canadian science prodigy winner of prestigious international competition
6/8/2018
Sajeev Kohli, a Grade 11 student from Waterloo, Ontario, receives top honours in the Global Healthcare Challenge
-
FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes
5/22/2018
The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin).
-
Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease
5/16/2018
BIVV003 is a gene-edited cell therapy candidate for the treatment of people with sickle cell disease
-
Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis
5/16/2018
U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018
-
The Digital Therapeutics Alliance Announces New Members
5/8/2018
The Digital Therapeutics Alliance (DTA) welcomes nine companies to membership
-
Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients
5/1/2018
Sanofi and Regeneron Pharmaceuticals, Inc. announced they will lower the net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access from Express Scripts.
-
Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients
5/1/2018
Regeneron Pharmaceuticals, Inc. and Sanofi today announced they will lower the net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access from Express Scripts.
-
Innovative Targeting Solutions Announces Antibody Research Collaboration with Sanofi
5/1/2018
Innovative Targeting Solutions Inc., (ITS) the global leader in the discovery and optimization of antibodies, today announced a research collaboration with Sanofi.
-
Berkeley Lights' Announces New Agreement With Sanofi for Beacon® OptoFluidic Platform
4/19/2018
Berkeley Lights, Inc. (BLI) announced today Sanofi purchased the Beacon platform to accelerate their cell line development (CLD) process.
-
Bioverativ Highlights the Impact of Humanitarian Aid in Hemophilia
4/17/2018
More than 15,000 people with hemophilia in 40 developing countries have already been treated following Bioverativ and Sobi’s unprecedented donation of factor therapy to the WFH Humanitarian Aid Program
-
According to HBM Partners, a healthcare investing firm, out of the drugs approved over the last five years, 63 percent originated at smaller companies.
-
New survey reveals many misconceptions exist about allergies, illustrating the need for greater education
3/27/2018
Sanofi teams up with television personality Adam Savage and allergist Dr. Neeta Ogden to help dispel common allergy misconceptions with facts
-
FDA approves Toujeo® Max SoloStar®
3/27/2018
Max SoloStar holds more insulin than any other long-acting insulin pen
-
For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.